Rhythm Pharmaceuticals (RYTM) Net Equity Issued and Repurchased (2017 - 2025)

Rhythm Pharmaceuticals (RYTM) has 7 years of Net Equity Issued and Repurchased data on file, last reported at -$188.7 million in Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$188.7 million in Q4 2025; TTM through Mar 2026 was -$34.0 million, a 129.32% decrease from a year earlier, with the FY2024 full-year figure at $138.8 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at -$188.7 million, down from $154.6 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for RYTM reached as high as $161.7 million in Q1 2021 and fell as low as -$188.7 million in Q4 2025.
• Historically, Net Equity Issued and Repurchased has averaged $18.1 million across 4 years, with a median of $14.1 million in 2022.
• Across the five-year window, Net Equity Issued and Repurchased jumped 282860.0% in 2022 and tumbled 445.7% in 2023, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at -$5000.0 in 2021, then soared by 282860.0% to $14.1 million in 2022, then tumbled by 445.7% to -$48.9 million in 2023, then tumbled by 285.99% to -$188.7 million in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were -$188.7 million in Q4 2025, $154.6 million in Q3 2025, and $34.0 million in Q1 2025.